{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=53", "query": { "intervention": "Protein Control", "page": 53 }, "page_size": 10 }, "pagination": { "page": 53, "page_size": 10, "total_count": 3499, "total_pages": 350, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=54&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=52&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T19:53:27.568Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03043053", "title": "The Effects of Oxytocin in Obese Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "oxytocin nasal spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 61, "start_date": "2017-07-01", "completion_date": "2022-07-07", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-10-31T19:53:27.568Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03043053" }, { "nct_id": "NCT04514653", "title": "RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD)" ], "interventions": [ { "name": "Ranibizumab", "type": "BIOLOGICAL" }, { "name": "ABBV-RGX-314 Dose 1", "type": "GENETIC" }, { "name": "ABBV-RGX-314 Dose 2", "type": "GENETIC" }, { "name": "ABBV-RGX-314 Dose 3", "type": "GENETIC" }, { "name": "Local Steroid", "type": "DRUG" }, { "name": "Topical Steroid", "type": "DRUG" }, { "name": "ABBV-RGX-314 Dose 4", "type": "GENETIC" } ], "intervention_types": [ "BIOLOGICAL", "GENETIC", "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 146, "start_date": "2020-08-25", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-31T19:53:27.568Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04514653" }, { "nct_id": "NCT00408629", "title": "Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "adalimumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2006-11", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2011-05-03", "last_synced_at": "2026-10-31T19:53:27.568Z", "location_count": 36, "location_summary": "Anaheim, California • Wheat Ridge, Colorado • Hamden, Connecticut + 29 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Wheat Ridge", "state": "Colorado" }, { "city": "Hamden", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408629" }, { "nct_id": "NCT00524472", "title": "Outcomes Study of Hyperinsulinemic Glucose Control in Cardiac Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiac Surgery" ], "interventions": [ { "name": "Hyperinsulinemic-normoglycemic clamp", "type": "OTHER" }, { "name": "insulin at the standard of care levels", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 1439, "start_date": "2007-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2018-10-26", "last_synced_at": "2026-10-31T19:53:27.568Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524472" }, { "nct_id": "NCT01593605", "title": "Resveratrol-Leucine Metabolite Synergy in Pre-diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Impaired Glucose Tolerance" ], "interventions": [ { "name": "Resveratrol", "type": "DIETARY_SUPPLEMENT" }, { "name": "resveratrol /HMB", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo treatment", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2012-02", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-10-31T19:53:27.568Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01593605" }, { "nct_id": "NCT01098266", "title": "NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "NGR-hTNF plus Best Investigator's Choice (BIC)", "type": "DRUG" }, { "name": "Placebo plus Best Investigator's Choice (BIC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AGC Biologics S.p.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2010-04-12", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2019-09-17", "last_synced_at": "2026-10-31T19:53:27.568Z", "location_count": 7, "location_summary": "Corona, California • Duarte, California • Tampa, Florida + 4 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01098266" }, { "nct_id": "NCT07000851", "title": "Imaging Studies in Corticobasal Syndrome", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cortico Basal Degeneration", "Corticobasal Syndrome", "Corticobasal Syndrome(CBS)", "Corticobasal Degeneration", "Corticobasal Degeneration (CBD)", "Corticobasal Syndrome (CBS)" ], "interventions": [ { "name": "C-11 ER176 Radiotracer", "type": "DIAGNOSTIC_TEST" }, { "name": "C-11 PiB", "type": "DIAGNOSTIC_TEST" }, { "name": "AV1451 Tau", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Jennifer Whitwell", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-06-25", "completion_date": "2031-03-30", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-31T19:53:27.568Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07000851" }, { "nct_id": "NCT00324831", "title": "GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "autologous immunoglobulin idiotype-KLH conjugate vaccine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "sargramostim", "type": "DRUG" }, { "name": "vincristine", "type": "DRUG" }, { "name": "Intervention/procedure", "type": "PROCEDURE" }, { "name": "antibody therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "chemotherapy", "type": "PROCEDURE" }, { "name": "colony-stimulating factor therapy", "type": "PROCEDURE" }, { "name": "cytokine therapy", "type": "PROCEDURE" }, { "name": "monoclonal antibody therapy", "type": "PROCEDURE" }, { "name": "non-specific immune-modulator therapy", "type": "PROCEDURE" }, { "name": "therapeutic procedure", "type": "PROCEDURE" }, { "name": "tumor cell derivative vaccine", "type": "PROCEDURE" }, { "name": "vaccine therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Favrille", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 480, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-18", "last_synced_at": "2026-10-31T19:53:27.568Z", "location_count": 2, "location_summary": "Beverly Hills, California • Chapel Hill, North Carolina", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324831" }, { "nct_id": "NCT01715753", "title": "Measuring Eating, Activity and Strength: Understanding the Response -Using Protein", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Weight Loss" ], "interventions": [ { "name": "Protein supplementation", "type": "DIETARY_SUPPLEMENT" }, { "name": "Diet counseling and group education lessons", "type": "BEHAVIORAL" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 71, "start_date": "2012-09", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2018-12-12", "last_synced_at": "2026-10-31T19:53:27.568Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01715753" }, { "nct_id": "NCT04938635", "title": "Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Beta-Thalassemia" ], "interventions": [ { "name": "VIT-2763 60 mg QD", "type": "DRUG" }, { "name": "VIT-2763 60 mg BID", "type": "DRUG" }, { "name": "VIT-2763 120 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vifor (International) Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": "2021-09-20", "completion_date": "2023-07", "has_results": false, "last_update_posted_date": "2022-11-10", "last_synced_at": "2026-10-31T19:53:27.568Z", "location_count": 1, "location_summary": "Whittier, California", "locations": [ { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04938635" } ] }